JUVEDERM 24HV, JUVEDERM 30 AND JUVEDERM 30HV GEL IMPLANTS
Allergan · Decision date Jun 2, 2006
What did the FDA approve?
FDA PMA P050047 was approved for the JUVEDERM 24HV, JUVEDERM 30, and JUVEDERM 30HV gel implants. The record here names the approved product family and does not describe any change from a prior version, so the exact relationship to an original PMA beyond this approval entry is not stated in the supplied text.
The source statement gives the labeled injection plane, mid to deep dermis, and the stated purpose, correction of moderate to severe facial wrinkles and folds such as nasolabial folds. It does not provide supporting study results, device construction details, or any broader clinical claims beyond that reported indication.
FDA approval order statement
APPROVAL FOR THE JUVEDERM 24HV, JUVEDERM 30 AND JUVEDERM 30HV GEL IMPLANTS. THE DEVICE IS INDICATED FOR INJECTION INTO THE MID TO DEEP DERMIS FOR CORRECTION OF MODERATE TO SEVERE FACIAL WRINKLES AND FOLDS (SUCH AS NASOLABIAL FOLDS).
- Regulatory pathway
- Original PMA
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Jun 2, 2006
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P050047
- Regulatory pathway
- Premarket approval application
- Applicant
- Allergan
- Product code
- LMH
- Decision code
- APPR
- Decision date
- Jun 2, 2006
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P050047 received
Application receipt date recorded by FDA.
P050047 · FDA decision
APPR
P050047/S106 · Related supplement
Juvéderm Ultra XC; Juvéderm Ultra Plus XC
Timeline entries are records held by MedtechLedger for P050047. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P050047
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
saypha ChiQP250021/S001 | Croma-Pharma GmbH | PMA supplement | Oct 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Allergan
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2525 Dupont Dr., Irvine, CA, 92612
Sources and methodology
- Original FDA record: P050047
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



